Benzinga | Aug 3, 2021 04:31PM EDT

Rigel Pharmaceuticals Q2 EPS $(0.08) Beats $(0.11) Estimate, Sales $26.27M Beat $20.37M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $26.27 million which beat the analyst consensus estimate of $20.37 million by 28.94 percent. This is a 63.95 percent increase over sales of $16.02 million the same period last year.